Epstein Apoptosis

When EBV-infected cells undergo apoptosis or lysis, the process involves the breakdown / death of infected cells and the release of viral components alongside intracellular cellular materials. This may include viral particles, cellular debris, intracellular proteins and metabolites, nucleic acid fragments, and damage-associated molecular patterns (DAMPs). 

These molecules can interact with the innate immune system by activating pattern recognition receptors, which in turn may trigger downstream inflammatory signalling pathways. 

Clinically, this immune activation may present as

• Temporary increase in pre-existing symptoms

• Transient fatigue

• Heightened sensitivity to stress

• Cognitive fatigue

• Low-grade flu-like feelings

• Headaches 

• Myalgia

These manifestations are generally reflective of immune system engagement and inflammatory signalling rather than the presence of circulating toxins or a toxin clearance process. In most instances, any symptom changes are self-limiting and will resolve within 1 - 2 weeks. Where necessary, reducing supplemental dosing is indicated to relieve symptomology and gradually return when as tolerated.